drugset / Trial / NCT02201394

Reversing Ticagrelor's Effects With Fresh Platelets

NCT02201394 ↗

Non-randomizedSingle-groupOpen-labelTreatment

Summary

Acute coronary syndrome (ACS) patients treated with antiplatelet drugs who require coronary artery bypass grafting (CABG) surgery have to wait 5-7 days for the effects of the drugs to wean off. This treatment-devoid period leaves the patient vulnerable, therefore any means to shorten this period could be useful. The present study aims to investigate the possibility of reversing the antiplatelet effects of ticagrelor with the help of fresh donor platelets. Fresh platelets will be added to blood samples of treated patients in varying concentrations at specific timepoints to determine the time and amount of fresh platelets needed to normalize platelet reactivity in the treated samples.

Timeline

Start
2014-07
Primary completion
2016-06
Completion
2016-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Aspirin Small molecule 81 mg —
Subject Aspirin Small molecule 325 mg —
Subject Ticagrelor Small molecule 90 mg —
Subject Ticagrelor Small molecule 180 mg —